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INTRODUCTION 
National expenditures for hospital care have in-
creased significantly since the mid-1960s, rising from $13.9 
billion in 1965 to about $99.6 billion in 1980, a gain of 
nearly 617 percent. These increases have led to a wide-
--------
-----sprean concernregar-dTn-g-Tfi_e_hTgfi .. r-afe-oT incre-ase in has-
pital costs (1-6). Because of the magnitude of the problem, 
officials of state health care programs now have incentives 
to reduce the rate of cost increase (2). The problem is 
more worrisome to the federal government since inpatient 
expenditures for elderly patients in the Medicare program 
rose from $4.5 billion in 1970 to $22.8 billion in 1980 
and were projected to rise another 33 percent by 1982 (1). 
Similarly, it was reported that health care spending in ~== 
1981 had reached 9.8 percent of the gross national product. 
Federal spending for Medicare accounts for $73 billion, of 
which $42 billion was spent on hospital care alone (3). 
At the same time, hospital expenditures for drugs in the 
United States have increased from $1 billion in 1972 to 
$3 billion in 1982 (4). 
In fact, the government has been attempting to shape 
the health field since before World War I leading to sub-
stantive legislation at the federal level in the 1940s (5). 
In the early 1960s, the growth of the gross national prod-
duct was reasonably strong, inflation was moderate, and 
1 
2 
health care costs, although high, were deemed affordable. 
It is to be noted that the legislation from the 1940s, 
1950s, and early 1960s was supply oriented. But in the late 
1960s, the philosophy began to change. Federal and state 
governments began to be more concerned with cost. Re-
straints on expansion of the number of inpatient beds and 
approach by health policy planners (2,5,7). Several laws 
had been passed concerning health care programs including: 
Medicare and Medicaid (1965), Neighborhood Health Center 
support (1965), and the Comprehensive Health Planning Act 
(1966). Further, Bills,~~., (2) reported that" .•• 
Congressional programs were passed and included the Nixon 
Administration's Economic Stabilization Program operated 
from August 1971 to April 1974 which included specific 
rules to limit cost increases in hospitals nationwide. 
In addition, the introduction of the Carter Administra-
tion's hospital-cost containment proposal in early 1977 
and the subsequent consideration of that proposed by Con-
gress increased the states' interest and the regulators' 
ability to restrain cost increases." 
It was noted that the traditional cost-based reim-
bursement system had a lot of problems in terms of fair-
ness, comprehensiveness, and sensitivity to the major 
variables affecting hospital cost. Davies,~~., (8) 
demonstrated the shortfall encountered with the tradi-
tional reimbursement system which includes: 
3 
a- The use of patient day as a unit of service for 
cost and reimbursement. 
b- The lack of true incentives for health care pro-
viders to contain costs. 
c- A definition of cost that does not cover the full 
financial elements of the hospital. 
d- Most trad it ional __ ~yste_m_s __ d_o_ no·t ap_p Ly _to _alL pay_e_r_s_,_-~-~-~ ~--" 
but rather some defined subset of major payers. 
e- Lack of comparability of costs across institutions. 
f- Institutionalized cost behavior of high cost pro-
viders. 
g- Lack of sensitivity and fairness with respect to 
case-mix (the type of services an institution 
provides) differences [for definition of case-mix 
data items, see Appendix A]. 
Davies suggested that because of these and other prob-
lems, hospital administrators, hospital regulators, legis-
lators, and other interested parties have examined alterna-
tive health care provider reimbursement methodologies. The 
most widely publicized alternative was the use of Diagnosis 
Related Groups (DRGs) to classify patients into homogeneous 
groups to reimburse hospitals. The DRG alternative is one 
method of Prospective Payment System (PPS). Other methods 
of PPS include: Capitation, Preferred Provider Organiz-
ations (PPOs), Health Maintenance Organizations (HMOs), 
etc. However, discussion of these methods is beyond the 
scope of this study. 
-----
--
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Curtiss in two separate reports (9,10) and others (11) 
indicated that the most recent and pervasive changes were 
imposed by Congress in PL97-248, "The Tax Equity and Fis-
cal Responsibility Act (TEFRA) of 1982" signed by Presi-
dent Reagan on September 3, 1982. The TEFRA cost-per-case 
imposed limits on Medicare payments to hospitals, which 
represent approximately 40% of average h~s{)i_~B:~- rE:!veiHl_~._ ___ _ 
~---------
TEFRA limits were applied only to hospital fiscal years 
beginning on October 1, 1982 to September 30, 1983. Be-
gining October 1, 1983, hospitals were to be paid at a 
fixed rate for care provided to a Medicare inpatient 
within a particular DRG. The DRG system will be phased 
in over fiscal years 1984-1987, i.e., there will be a 
gradual transition from cost based reimbursement to rate-
based set retrospectively. 
In general, these reports indicated that there is a 
change from the eras of exciting, new opportunities, chance 
of creativity in clinical implementation, system develop-
ment and improving of quality of care to a different 
dilemma, that is, an era of lack of money (12). However, 
Enright (7) emphasized that "whereas hospitals in the past 
were rewarded for spending more, now they will be rewarded 
for cutting cost and improving productivity." 
On the other hand, several writers (1,12) pointed out 
that the bulk of the increase in hospital expenditures was 
attributable to factors outside the control of hospital 
managers, such as inflation and the growth and aging of the 
W-
5 
population. Zilz (12) summarized the problem by saying 
that the problem has many factors including: increased 
United States population, increased number of elderly, 
health care expenditures rising faster than inflation in 
other industries, and a mismanagement of health care re-
sources. 
--~~~~--~-----
1. What are DRGs? 
1. A. Definition 
Diagnosis related groups (DRGs) represent a homogen-
eous grouping of patients who require roughly the same 
treatment of care, and thus it is assumed they will use 
similar amounts of hospital resources. In other words, 
it is assumed that the quality and nature of the resources 
consumed by patients are similar within a DRG, yet dif-
ferent across DRGs (3,6). The criteria that were used to 
define DRGs are (13): 
a- All patients were to be assigned to a DRG (ex-
haustive) and any given patient was to be assigned to one 
and only one DRG (exclusive). 
b- These DRGs should be manageable in number; that 
is, no more than 500 DRGs. 
c- Differences in length of stay (LOS) were not sta-
tistically significant. 
d- They are based on the Uniform Hospital Discharge 
Data set: diagnosis, surgical procedures, patient age, 
and discharge status. 
6 
1. B. Development and Purpose 
DRGs were developed primarily at Yale-New Haven Hos-
pital in the early 1970s by health services researchers, 
Robert Fetter, John Thompson, and Richard Averil. The 
researchers were interested in defining expected LOS so 
that utilization review activities could be focused on 
believed that DRGs would identify and describe the hos-
pital's major products, and therefore, be used for cost 
control and for determining hospital reimbursement ca-
tegories and rates (3). 
1. C. Classification 
Doremus, et al., (18) and others (1,6,15,16,17) 
reported that to date there have been two sets of DRGs 
developed. The original set, based upon the ICDA-8 coding 
scheme, included medically similar patients, and were ca-
tegorized into 83 major diagnostic categories (MDCs) based 
on the primary diagnosis. These MDCs subsequently under-
went a subgrouping analysis based upon LOS consideration. 
This was achieved using an interactive computer system 
known as "AUTOGP" (automatic grouping system). AUTOGP was 
designed to facilitate rapid analysis of complex medical 
information yielding results of a uniquely high statisti-
cal and medical quality (16). This original set of the 83 
MDCs consisted of 383 DRGs. The latest set, based upon 
the more extensive ICD-9-CM coding scheme, was develop-
LL 
,, 
f: 
~-
~--
~ 
~ 
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ed by the Health Care Financing Administration (HCFA), and 
consisted of 467 DRGs aggregated into 23 MDCs (3,9,13,18). 
It is important to mention that the first generation 
DRG system had several limitations. The most important 
limitations were low clinical coherence and limited accep-
tance of the system by physicians. Furthermore, the com-
paratively small, geographically unrepresentative sample 
of patients used to develop DRGs undermined applicability 
of the system nationwide (13). Bills, ~ ~·, (2) in 
their study showed that evaluation of the early phases of 
state efforts to control hospital costs led to discour-
----
aging conclusions about the effectiveness of such programs. 
However, the new DRGs specify separate payment rates for 
urban and rural areas, expand the number of DRGs, and 
propose adjustments for differences in area hospital wage 
levels compared to national averages (20). 
Beginning in October 1983, DRGs became the basis of 
payment for the federal government's version of the pro-
spective payment plan for hospitals. Curtiss (9) wrote 
that the prospective payment system is revolutionary in 
that hospital reimbursement for Medicare patients will 
be based almost exclusively on DRG rates, regardless of 
actual hospital cost. 
It was stated by others (3,19,21) that hospitals 
receive the same rate for all patients within a DRG re-
gardless of LOS or amount of services consumed, i.e., what 
a hospital receives for the care of a patient will be di-
-------
~=======================~=-=-~-~~---------------... ---
~-
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agnosis-related but not related to what the hospital 
spends. Thus a clear incentive exists for administrators 
to minimize costs because reduced expenditures will mean 
more hospital income. 
1. D. Impact on Hospitals 
It is clear that rate-based reimbursement puts has-
pitals at a financial risk to varying degrees, depending 
upon the unit of service to which the price is fixed (9). 
Therefore, for the sake of institutional survival, ad-
ministrators will be initiating programs that are design-
ed to minimize services to individual patients without 
compromising treatment success (21). 
In contrast to the traditional reimbursement system, 
where hospitals are paid after services have been provided 
to patients, prospective rate-setting programs set a pre-
established fixed charge for a service prior to the period 
for which the service is to apply (17,19). 
It is theorized that it could be possible to compare 
relative performance between hospitals. As a result, 
efficient hospitals can be identified and rewarded. This 
incentive will encourage efficiency which will help con-
trol hospital costs. 
1. E. Participating States 
Maryland, Massachusetts, New Jersey, and New York 
will not have to participate in the new plan for a few 
9 
years because these four states have their own. cost-con-
tainment program (12,23). All other states are sched-
uled for a phase in plan over four years, which began in 
October 1983. 
1. F. Hospitals Covered Under PPS 
Prospective pricing applies to all hospitals (in-
eluding rural hospitals operating fewer than 50 beds) 
with the exception of the following (7,9,11,20,24): 
1. Long term care hospitals (average LOS over 25 days). 
2. Pediatric hospitals and units (patients under 18 
years of age). 
3. Certified psychiatric hospitals. 
4. Rehabilitation hospitals. 
5. Psychiatric and rehabilitation units of general 
hospitals, if these units have separate admission and 
discharge polices. 
6. Hospitals that can establish sole community 
provider status by providing the sole source of local care 
and geographical separation from alternate sources of 
hospital care. 
7. Hospitals treating a high volume of low income 
or Medicare beneficiaries and public hospitals. 
8. Regional referral centers. 
9. Specific cases (patients) with extraordinarily 
long LOS "Outliers." See Appendix B for definition of 
outliers. 
H 
~= 
10 
10. Hospitals extensively involved in the treatment 
of and research on cancer. 
2. Expectations About DRGs 
-----
-·------
Being a new experiment, DRGs are in the center of pub-
lie debate with roughly an equal number of supporters and 
--
d e t r a c t or s _it n d ,_p~!"_ h a p_ s_, __ <!__l_<!_r_ g ~ gr- o UJ>_ u _n c o ll1 m i_t t e_ d __ (_5 ) . ______ _ 
2. A. i. Fears and Limitations (6,17,25) 
Under PPS, there is a fear of inaccurate reviewing, 
explanation, or coding of patient data, which may result in 
misrepresentation, and therefore, cannot be used to measure 
resources or to accurately predict reimbursement needs. 
This is particularly true since the overall system-relies 
on abstract data that may contain misclassification and 
coding errors which can fail to include all diagnoses. 
Van Etten (27) pointed out three major problems en-
countered that may affect the success of the new system. 
First, the clinical and financial information are separate. = ~ 
Second, clinicians are not integrated into the management Iii 
process. Thirdly, there is improper management of product-
ivity in terms of intermediate and endproduct management. 
In addition, collecting detailed quality assurance data 
is either impractical for most hospitals or it requires a 
tremendous amount of additional work for hospitals (26). 
On the other hand, Kreitzer,~~., (17) and others 
(6,28) reported early that the overall DRG concept has 
.;====================================== ------
---------
----- -
--- ------- -------
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failed to consider the most essential patient character-
istic, namely, severity of illness. They believe that 
this characteristic correlates with the intensity of ser-
vices provided and the amount of resources utilized. 
Horn (29) in her study reported a positive relationship 
between severity of illness and the hospital and laboratory 
charges, LOS, n urn be r of_ c:_o_I!_ su_l t ~-~ i()f1S_,_Ci11<Lill~l't_(l_l_i_f:y_ T?t~e-=:cs~·--
Several studies addressed the hospital's behaviour 
in response to the new reimbursement system. Wagner (30) 
suggested that " ••• getting a patient well, quickly, and 
with minimum use of resources can create an incentive 
payment, but it may leave you (the hospital) with a pa-
tient complaining about a high bill for what he or she 
perceives as a short stay with little service." Similar-
ly, it was stated by others (26) that "Some hospitals 
might curtail needed services to patients, thereby cut-
ting costs and increasing profits." 
In addition, there is a concern that hospitals will 
deny or restrict access to care rather than meeting the 
challenge of managing better and being more cost effec-
tive (20). Further, prospective payment systems give 
hospitals incentives to discharge the patient early. 
However, as stated by Nestler (26), such behaviours are 
unlikely, since the attending physician is not going to 
discharge a patient prematurely. 
Another potential problem was expressed by McNerney 
(5) in that the hospital will shift from a philosophy of 
;=;---
H 
~--­
!2..,____ 
~ 
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cure to one of treating symptoms. This point was sup-
ported by Hally (14) who mentioned that the most threat-
ening aspect of the DRGs payment system is its impact on 
patient care. In his opinion, many diagnoses can neither 
be clearly defined nor treated in a similar manner. He 
added that the problem with DRGs is it simply measures 
cost e f f i c i_E:_Il_c:_y__a_nd _<!_o e~ ng t:_ cons icle r_ w het:h_e r __ Q_I'__n_ot _ t_h_e _____ _ 
patient is cured. Moreover, he mentioned that there is a 
risk that the product will be cheapened to reduce costs 
which sacrifices patient care. 
Escalating diagnosis by coding cases into higher cost 
DRGs, termed "DRG creep," as well as discharging patients 
early and readmitting them, or "gaming" the system by 
admitting lower-cost illness, represent another limita-
tion of the system (5,6,9,31). Mahonly, (31) executive 
director of the area I Professional Standard Review 
Organizations (PSROs) in Madison, however, said that "the 
PSRO can easily detect that practice." This could be true 
since the quality review systems as established by the 
PSROs contain the following elements: 
1. Admission certification; 
2. Continued stay review; 
3. Validation of diagnoses and procedures; 
4. Ancillary review; 
5. Discharge planning; 
6. Medical care evaluation studies; and 
7. Profile analysis. 
~=­
~--
:~ 
;;======---=-=~~-=-========-=-------__ _ 
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Curtiss (9) stressed that the Departement of Health and 
Human Services (HHS) plans to combat DRG creep through a 
use-review program of hospital and physician admission 
patterns, as well as a DRG verification- audit. 
Additional fears and negative views include the 
following (1,5,14,26,32,33): 
a- Hos pi t_a_l_s_w_il_l_b_e __ pa Ld_ appr-oxima-tely -t-he--same --
standard fees and therefore will enjoy little surplus in 
the long run. 
b- The new system may put some hospitals at risk if 
they cannot share services with another hospital to pro-
vide care· for certain types of its patients. 
c- The new system unavoidably introduces more work 
on the medical records staff in terms of DRG documentation 
and chart review. 
d- Some hospital officials claim DRG reimbursement 
slows improvement in the quality of medical care by making 
it more difficult for hospitals to obtain needed, improved 
technology. 
e- There is fear that the physician's preoccupation 
with price will lead to increasing the adversarial rela-
tionship between the medical staff and the hospital, which 
may lead to unbundling of services (5). 
2 • A. ii. Adverse Effects of DRGs on Hospital Pharmacists 
DRGs created additional pressures on hospital pharma-
cists which can be summarized as follows (12,23,27,32): 
14 
1. Conflicting pressure from hospital administra-
tors, representatives of drug industries, and physicians' 
prescribing patterns. 
2. They are no longer an important revenue center. 
3. Expected to assume responsibility for no more 
than cost. 
4. Concern regardiil_g_ ~ist!"_ibut:Jon C:()St_s_a!l_cl__ho\V __ 
they affect total cost, e.g., unit dose. 
5. To balance quality and services with financial 
management issues to cope with the health care environment 
of the future. 
2 • B. Positive Views 
In spite of the previously listed negative views, 
some of which have already been solved or are being solved, 
there are tremendous positive views and good news regard-
ing DRGs (1,2,5,6,15,20,21,25,27,30,31,34,35): 
1. DRG reimbursement encourages physicians, nurses, 
heads of ancillary departments, financial officers, and 
other staff members to work together as a team to render 
care efficiently and to expedite the flow of correct 
paperwork. 
2. Patient care must be monitored since the pricing 
system set up incentives to discharge a patient as quick-
ly as possible and to restrain unnecessary testing. 
3. Pharmacists will no longer use high drug charges 
in order to provide more revenue to the hospital. 
15 
4. The new system gives significant additional in-
fluence and authority to the pharmacists. 
5. DRGs will require hospital pharmacists to restrict 
their formularies, and make greater use of generic drugs. 
6. DRGs may prove to be an effective way to monitor 
and control costs and utilization of hospital services. 
7. The DRG system will facilitate the preparation of 
!--------------- -- --- ---------- -- - ~~------~~-~- ~~---~~-~ -- ------
annual management reports by the State Department of Health. 
8. It allows determining those DRGs for which the 
hospital may exceed the average in LOS or in the cost of 
service rendered. These DRGs could be monitored on a 
regular basis. 
9. PPS significantly decreases the annual rate of 
increase in hospital costs (2). 
10. DRGs can be used not only for reimbursement but al-
so for budgeting, planning, and quality assurance programs. 
11. It will force hospitals to supply the best possi-
ble patient care at the lowest cost. 
1 2 • Physicians may integrate "cost" as a part of the 
equation of hospital care. 
13. Computerization becomes crucial for the hospital 
to identify potential financial problems. Computers per-
form data organization and report preparation in a timely 
and accurate manner. In addition, it explores an insti-
tution's "market basket" of service (35). 
14. DRGs can be used as a unit for comparison and 
payment especially in the competitive environments. 
;' 
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It is concluded that DRGs will provide previously 
unavailaole information and will serve as a promising sys-
tern to monitor and control hospital resource utilization. q __ _ ~ 
In addition, the DRG system encourages-hospital pharmacists 
to put their expertise into practice by educating the 
physician on cost-effective drug therapy alternatives. 
3-.---Hospital~rategies-For-sllrvival 
The current financial and competitve pressures are 
forcing institutions to develop new strategies for sur-
vi val. Strategies must be employed to develop incentives 
to reduce the cost of inpatient acute-care services and 
to increase productivity (38). 
Several reports (15,16,18,25) emphasized that review-
ing and confirming the accuracy of diagnostic and surgical 
data by appropriate retrospective audit should be initiated 
as the first step. Also, apparent contradiction between 
clinical and billing data should be eliminated for the 
current case-mix based on DRGs in order to measure re-
= ~ 
source use precisely and predict reimbursement accurately. iii 
Further, these data found in the medical records should 
be improved to the extent that they can be considered 
reliable not only for case mix determination but also for 
management reporting, quality assurance, utilization re-
view, diagnostic costing, program planning and research, 
Mills, ~ ~·, (16) believe that AUTOGP makes an 
important contribution by handling complex data analysis 
r=============----------=-=-~==----_ ---=--- ---
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especially when large n~mbers of 6bservations are in-
valved with many variables identified per observation. 
Mills added that "in such cases efficient data manage-
ment is crucial if the analysis is to be cost effective." 
Sankey,~~., (37) have shown that the use of a 
more accurate method of cost allocation will assist hos-
pit a 1 ad mini s_t::_r a _1::()r s _in _d~t~tl1l:L11 :iD g_y.rh~1:::b e_r _ c_h_ar ge_s __ ac_c u_--_ _____ _ 
rately reflect the cost of the resources used to care for 
individual patients. Cost allocation should provide hos-
pital managers with one of the instruments they need to 
improve planning, budgeting, and hospital operations. 
On the other hand, Crane,~ al., (36) pointed out 
that costs have to be managed first before they can be 
contained. She found that 20 percent of her drug items 
account for 80 percent of her drug revenue. She con-
eluded that "It is prudent to separate the vital few from 
the trivial many." 
Medical records staff must thoroughly familiarize 
themselves with DRG documentation and perfect their abil-
ity to search and to interpret the charts in order to 
gather all relevant information. 
For these complicated issues, Grimaldi (1) stressed 
that hospitals need a full time employee who not only co-
ordinates departmental efforts to function with DRGs but 
also who is able to establish a good working relationship 
with diverse groups of personnel. This employee is the 
"DRG coordinator." The DRG coordinator will identify 
8-
= ~ 
iii 
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DRGs and departments that are encountering cost problems. 
Zilz (12) and others (3) reported that there is no 
doubt that administrative reorganization is a must. For 
example, if an efficient hospital is competing with many 
inefficient hospitals, the inefficient hospitals will stop 
providing services, because they are losing money, or they 
become more efficient to survive. II1 Zilz I wor_ds_,_ "_th? __ -------
bottom line is survival of our hospital at any cost ... 
through either discontinuing services, addressing the 
prescribing influence, reducing laboratory orders, freezing 
salary, and assigning proper personnel who efficiently do 
a specific job." 
Several institutional strategies were suggested by 
Bonney (38) in'responding to the financial pressure that 
have been outlined. The best strategy for institutional 
survival in his opinion is diversification. Horizontal 
diversification includes expanding hospital business into 
similar and complementary lines. Vertical diversification 
is described as establishing services other than those 
providing acute care. Health services include consul-
tation in areas in which they have expertise, continuing 
medical education or renting or buying health equipment. 
Nonhealth care business is unlimited and may include real 
estate, restaurants, etc. Bonney added that marketing 
strategies, either to physicians or to payers, is another 
major alternative that should be considered. 
In addition, development of information systems, is 
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important for hospitals to operate under PPS and to know 
the cost of treating patients in a specific DRG. This 
information system will help to establish a mechanism to 
determine the cost per DRG which would reflect the pro-
fitability of a part~cular service (38). 
Another strategy Bonney (38) has suggested is to 
reduce acute care inpatient services and to increase pro-
~~- -~~ --~~-- ----- ---
ductivity. He wrote that one way to achieve this is to 
reduce the peak service demand for ancillary s~rvices. 
Improving medical practice and proper utilization of 
ancillary services is another strategy that will result 
in high profitability (5,27). Figure 1 represent the 
relationship between case-mix, medical practice, product-
ivity, and profitability from the chief financial officer 
point of view, as suggested by Van Etten (27). He pointed 
out that there is a significant difference in LOS, admis-
sian rate, and ancillary utilization by states and has-
pitals. Van Etten attributed that to the differences in 
medical practice which, as he mentioned, can be controlled 
by case mix which in turn leads to increased profitability. 
It is to be concluded that the future belongs to 
those who can identify community health care needs and 
then organize and market a delivery system to efficiently, 
effectively, and economically meet the need. In contrast, 
Bonney (38) commented that "Those hospitals that play 
"ostrich" by burying their heads in the sand and continue 
with "business as usual" will be soon out of business." 
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Figure I. The Relationship between Case Mix, Medical Practice, 
Productivity, and Profitability. 
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4. Pharmacy Management Strategies 
In the era of constrained reimbursement and intense 
competition, pharmacy departments are making reducing cost 
a top priority (39). Hospital pharmacists have a great 
and unusual opportunity to reduce pharmacy operating ex-
penses by eliminating unnecessary prescribed drugs and 
equivalent drugs. 
Specific recommendations (12,23,27,34,40-43) have been 
made to control pharmacy costs and are summarized as follow: 
1. Reduce the price per unit purchased. 
2. Decrease the size and dollar value of drug 
inventory. 
3. Implement a restricted drug formulary. 
4. Perform drug use reviews. 
5. Educate physicians on the relative cost of alter-
native therapies. 
6. Educate the patient and physician about medication 
errors. 
7. Reduce drug serum assays. 
8. Use efficient dispensing and distribution of drugs. 
9. Perform tough negotiation regarding drug cost. 
10. Work closer with other departments. 
11. Computerize the detection of drug interactions, 
allergies, etc. 
12. Reduce drug deliveries to nursing units. 
13. Quantify and reduce pharmacy waste. 
,, 
t__;_ 
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14. Identify and label expensive drugs in the pharmacy. 
15. Notify head nurses of the cost of expired drugs. 
16. Remove skin test products from nursing units and 
change to unit dose issue. 
17. Perform comparative analyses of drug cost within 
the hospital and between hospitals. 
Raymond ( 44) s ugiLes!ed _that pharmacy d epar tm_e11t_ ~tra1::=-
egies should be targeted at three major areas, human re-
sources in terms of productivity and efficiency, material 
resources in term of cost control and product decision 
making, and system resources in terms of installment of 
audit trail, documentation of use, and cooperation between 
health care providers. 
Another approach for pharmacy cost management was 
reported by Crane,~~ •• (36) who pointed out that there 
are three major factors that should be kept in balance: 
1. Administrative management: purchasing, inventory, 
negotiation, and price comparison. 
2. Clinical management: ·providing current and con-
tinuous support to physicians regarding drug cost and al-
ternatives, patient education programs, influence pre-
scription habits, and drug utilization review. 
3. Distributive management: equipment and personnel 
management, dosage form and unit dose distribution, check-
ing dose frequency and schedules, and personnel efficiency 
distribution. 
The pharmacy's focus, therefore, could be to identify 
~ !'! --
~= --
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outlier case-type, bridge the gap between medical and ad-
ministrative staff, be concerned about cost not charges, 
increase productivity, and provide a system to collect and 
analyze data related to drug costs and case type (27). 
Upton and associates (45) reported in their study 
that the pharmacist's consultation services to physicians 
regarding drug selection _8.I1d regimen design, co_up1ed _ _with_ 
patient compliance counseling, documented an annual saving 
in retail drug costs of $200 per patient. Upton added that 
"in addition to cost-saving, the average number of dosage 
units was reduced from 7.6 to 4.5, thereby encouraging 
improved compliance." 
Another area of the pharmacist's expertise when con-
sidering a drug for formulary status is to verify the manu-
facturer's claims regarding the introducti~n of a new and 
more expensive agent. One example of claims that should 
be verified includes that of reducing hospital stay re-
quiring fewer doses before a cure is achieved (7). 
Controlling drug costs in hospitals has been reported 
in many other studies (4,39,46). Mehl (4) listed several 
indicators that can be utilized for this purpose. These 
indicators include: calculating drug cost inflation index, 
cost per patient day and per clinic visit, cost per pre-
scription, pharmacological-cost indicator, disease-drug 
cost indicators, intravenous solution, and radiopharma-
ceutical-cost index. 
Purchasing, inventory control, and waste reduction 
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techniques to minimize non-personnel expenditures were 
reported by Abramowitz (39) and McAllister III (46). 
They wrote that cost-saving purchasing mechanisms includ-
ing competitive bidding, contract negotiation, group pur-
chasing, and primary wholesale~ purchasing were proven to 
be effective. 
In the era of prospective pricing, the hospital~ 
pharmacist will acquire new financial, clinical, and 
communication skills as well as new relationships with 
administrators, physicians, and nurses. McAllister 
stressed that for the hospital pharmacist to succeed, he 
must follow market trends, follow institutional use pat-
terns, and understand the complicated interrelationship 
between supply and demand and input and output to maximize 
the effectiveness of purchasing and inventory control ef-
forts. 
Finally, changing prescribing patterns were reported 
by Abramowitz (47) as an effective way to control finan-
cial variables. Using pharmacist~ to advise physicians 
regarding appropriate drug therapy will ensure the highest 
quality pharmaceutical services at the lowest possible cost. 
The author suggested that enough flexibility should be al-
lowed for more costly services or therapies to be used when 
required but those less costly should be used when suffi-
ient. He further added that the key to controlling pre-
scribing patterns will be through pharmacist involvement 
with formulary management, closing and maintaining the 
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formulary, Pharmacy and Therapeutics Committee, drug mon-
ographs, automatic stop orders, decreasing therapeutic 
duplicates, and restriction of drug use. 
All of the above mentioned skills and relationships 
will provide the pharmacist with factors necessary to 
succeed in the new reimbursement environment. 
In the past, the physician dictated the level of hos-
pital care provided to patients with little or no regard 
to cost. Now, cost will become an important factor since 
hospitals have an incentive to minimize expenditures (21). 
There are two components of cost, the hospital com-
ponent (laboratory procedures, drugs, etc.), and the pro-
fessional component (prescribing patterns, operating room 
hours, etc.). The second component is more difficult to 
manage. Shapleigh (27) in her study showed that there is 
evidence indicating a significant variation in medical 
practice patterns. On the other hand, she pointed out 
that there is a dichotomy between the hospital's payment 
incentives and those of physicians. 
For the hospital to survive in the changing reim-
bursement environment, physicians' strategies should be 
aimed at the following (9,20,27): 
1. Manage and limit hospital resource usage. 
2. Educational need about cost of drugs especially 
antibiotics, laboratory work, and unit of services. 
j_ 
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3. Synchronization of physician incentives with 
hospital incentives. 
4. Careful patient monitoring. 
5. Incentives to increase outpat~ent and home health 
care services. 
6. Efficient and accurate coding of diagnoses and 
procedures. 
It is predicted that doctors and hospitals will have 
a new interest in reform and collegial working relationships 
under the PPS for the sake of institutional survival (1,5). 
Van Etten (23) mentioned that "We developed a sophis-
ticated financial .system but we have not developed infor-
mation that shows clinical and financial cost." He added 
a--
that " .•• Everyone describes his own cost, e.g., pharmacy 
cost, laboratory cost, but nobody describes the case cost 
or the endproduct cost." 
To date, very few studies, if any, have been published 
evaluating and correlating clinical data to the variability 
of the patient's pharmacy charges within a DRG category. 
Upton and associates (46) proposed a specific plan of at-
tack focusing on an analysis of expensive DRGs. Evalu-
ating DRGs with high pharmacy charges was suggested as the 
first step in the analysis. Upton's plan was to intensify 
pharmacists' monitoring of patients having diagnoses with 
high pharmacy charges. 
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6. Purpose of the Study 
The purpose of this study is to evaluate financial 
and clinical data of patients within a selected DRG. The 
data obtained from such analysis will be used to design a 
system whereby clinical pharmacists may improve the hos-
pital's reimbursement potential. 
signed to evaluate all DRGs in a community hospital in an 
attempt to focus on those DRGs which represent the great-
est financial pressure to the pharmacy department and, 
therefore, to the institution. 
Clinical and financial data of patients within the 
expensive DRG, .will be collected from their medical and 
financial records for subsequent statistical analysis 
with special consideration to pharmacy charges. 
The ultimate objective of this study, though, is to 
provide a list of measures or parameters that may affect 
the patient's hospital charges. Using these parameters, 
the clinical pharmacists will be able to intensify their 
monitoring of patients with high pharmacy charges in an 
attempt to reduce their impact on patients' charges. 
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METHODOLOGY 
This study was designed to review and analyze DRGs 
at St. Joseph's Hospital, in Stockton, California. The 
main objective was to determine the relationship between 
clinical and financial data for patients within a DRG. 
The second objective was to identify patient-specific 
.information that may reflect high pharmacy charges and 
the need for clinical pharmacy intervention. The third 
objective was to propose criteria that may predict which 
patients need to be monitored in an attempt to control 
pharmacy charges within a selected DRG category. 
A. Patient Population 
All patients admitted to St. Joseph's Hospital, Stock-
ton, California, a 316-bed community hospital, between 
January 1, 1983, and August 31, 1983, were retrospectively 
assigned to DRGs. The Medical Records staff at the insti-
tution assigned a total of 10,550 patients to 390 DRGs 
using the system described by Grimaldi and Micheletti (1), 
the Medicare DRG list published in the Federal Register 
(49), and the International Classification of Diseases 
(50,51). 
Medical records staff were assisted in assigning DRGs 
by a computer program provided by Shared Medical Systemsa 
a Shared Medical System Corporation, 2041 Rosecrans 
Avenue, Suite 287, El Segundo, CA 90245. 
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which uses a computerized decision tree for categorizing 
patients. 
B. Study Design 
For the purpose of the present study, the 390 DRGs 
were ranked based upon their total pharmacy charges per 
DRG. From this original ranking, the top 20 DRGs were 
-----
~~­
---
-aeflned as the 20 most expensive DRGs for the pharmacy 
department (48). Subsequently, the following data were 
compiled for the defined 20 most expensive DRGs: 
1. Number of patients per DRG. 
2. Major diagnostic category (MDC). 
3. Total and mean pharmacy charge per DRG. 
4. Total and mean hospital charge per DRG. 
5. Mean length of stay (LOS) per DRG. 
6. Pharmacy charge as a percentage of hospital 
charge within each DRG. 
7. DRG distribution and total pharmacy charge by MDC. 
The 20 most expensive DRGs, for the pharmacy depart-
ment, by total pharmacy charges are listed in Table I. 
The compiled data were analyzed and correlated from 
different perspectives to select the most expensive DRG 
category (see page 32). Surgical and neoplastic categories 
were excluded by the study protocol. The most expensive 
medical category was subsequently chosen for the study as 
the prototype. 
The top five medical DRGs, excluding neoplastic cat-
egories, ranked by the average hospital charges, average 
R---
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.. 
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Table I 
The 20 Most Expensive DRGs by Total Pharmacy 
Charges for January-August 1983. 
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DRG 
107 
82 
148 
127 
88 
14 
96 
154 
105 
89 
197 
122 
Title a 
Coronary bypass(with & without 
catheterization) 
Respiratory neoplasm 
Major small & large bowel pro-
cedures; over age 69 or secon-
dary diagnosis or both 
Heart failure & shock 
Chronic obstructive pulmonary 
disease 
Specific cerebrovascular disorders 
except transient ischemic attacks 
Bronchitis & asthma; over age 69 or 
secondary diagnosis or both 
Stomach, esophageal, and duodenal 
procedures; over age 69 or 
secondary diagnosis or both 
Cardiac valve procedure with pump 
(with & without catheterization) 
Simple pneumonia & pleurisy; over 
age 69 or secondary diagnosis or 
both 
Total cholecystectomy with & without 
common duct exploration; over age 
69 or secondary diagnosis or both 
Circulatory disorders with acute 
myocardial infarction with and 
without cardiovascular compli-
cations; discharge alive 
Number 
of 
MDC b Patients 
5 
4 
6 
5 
4 
1 
4 
6 
5 
4 
7 
5 
171 
136 
76 
196 
110 
172 
121 
35 
15 
113 
95 
141 
To.tal 
Pharmacy 
Charges($) 
461,435 
103,921 
91,247 
78,524 
77' 931 
72,075 
65,879 
65' 148 
64,138 
60,992 
57,127 
56,488 
---------------------------------------------------------------
~---··---~~-· ·- -- ------- -----
31 
Table I (continued) 
Number Total 
-~-DRG------~--- Trtie-a~--- ----- h of ·Pharmacy MDC~ Patienis- -Cfiar-ge-s($)-~--~-
182 Esophagitis, gastroenteritis, and 
miscellaneous digestive diseases; 
over age 69 or secondary diag-
nosis or both 
403 Lymphoma or leukemia; over age 69 or 
6 
secondary diagnosis or both 17 
132 Atherosclerosis; over age 69 or 
secondary diagnosis or both 5 
125 Circulatory disorders (except acute 
myocardial infarction) with cardiac 
catheterization; uncomplicated 
primary diagnosis 5 
354 Nonradical hysterectomy; over age 69 
or secondary diagnosis or both 13 
370 Cesarean section with secondary 
diagnosis 14 
110 Major reconstructive vascular proce-
dure; over age 69 or secondary 
diagnosis 5 
366 Malignancy of female reproductive 
system; over age 69 or secondary 
diagnosis. 13 
a 
223 55,998 
56 55,111 
203 52,252 
442 51,923 
206 51,607 
191 51,543 
so 50,448 
56 45,371 
Based upon system described in Reference 1, pp. 290,308. 
b 
Major Diagnostic Category. 
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pharmacy charges, and average LOS are represented in 
Figure 2, 3, and 4 respectively. 
Based upon an evaluation of the data in Table I and 
Figures 2, 3, and 4, DRG 88 (Chronic Obstructive Pul-
monary Disease) was selected for further study. It was 
assumed that DRG 88, the medical DRG with high total 
________ _E_I-l_a_rmacy __ c_!l_1:1E_B~--~ff~_!ed the greatest potential for in-
vestigation with positive results. In addition, in 1983 
DRG 88 had a high mean hospital charge, LOS, and over 100 
patients were assigned to it. 
DRG 88 is in MDC 4, Diseases and Disorders of the 
Respiratory System. The DRG classification tree for that 
particular MDC is schematically represented in Figure 5. 
C. Sample Selection 
All patients within the selected medical DRG were 
ranked based upon their total pharmacy charges. Patients' 
frequenc.y distribution by pharmacy charges is presented in 
Figure 6. 
Based upon the frequency distribution by pharmacy 
charges, three subgroups were identified: below the median 
pharmacy charges (Group 1 < $450), between the median and 
mean pharmacy charges (Group 2, $451-900), and above the 
mean pharmacy charges (Group 3 > $900). 
Figure 7 shows the distribution of patients within 
the three groups, namely, group 1, 2, and 3. 
Fifteen patient were randomly selected from each 
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DRG Number 
Figure 2. The Top Five Medical DRGs by Average Hospital Charges. 
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group using a table of random numbers (53). Patients who 
died during hospitalization and those classified as out-
liers were included in the random selection of patients. 
D. Data Collection 
Comparative clinical and financial data, for the 15 
patients in the three groups, were collected using a spe-
cially designed data form. This data form includes: 
1, Patient medical record number. 
2. Patient's age, sex, and weight. 
3. Number of admissions. 
4. Primary and secondary diagnoses. 
5. Number of consultations. 
6. Patient's medical history. 
7. Number of individual laboratory test orders: 
-Number of x-ray orders. 
-Number of microbiology (culture/sensitivity) tests. 
a 
-Number of arterial blood gas (A.B.G.) orders. 
-Number of chemistry panel 1 & 2 orders (see App. 
-Number of urine analysis orders. 
-Number of electrocardiogram (E.K.G.) orders. 
-Number of blood analysis orders. 
-Number of drug serum levels performed. 
-Total number of laboratory orders. 
a 
8. Total number of drug dosage units. 
Refers to the frequency with which drug order codes 
were processed for billing purposes applied at 
St. Joseph's Hospital, Stockton, California. 
c). 
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9. Total pharmacy and hospital charges. 
10. Patient's length of stay (LOS). 
11. Operating room procedures. 
12. Discharge status. 
E. Data Analysis 
Clinical data were abstracted from each patient's 
---------- - -----
record, whereas financial data were compiled from the 
computer printout provided by the institution's billing 
office. 
Data for 17 variables for each of the 45 patients 
were manually collected, organized, and tabulated for 
subsequent computer data entry and analysis. 
The compiled data of the randomly selected 45 pa-
tients, representing the three groups, were subsequently 
a 
analyzed using a computer-based program. 
Basic statistics including mean, standard deviation, 
and the standard error were calculated. A correlation 
matrix of the 17 variables was performed to provide a 
useful tool to identify clinically and financially cor-
related variables. In addition, order statistics includ-
ing maximum, minimum, range, midrange, 25-th percentile, 
and 75-th percentile were computed for all the selected 
17 variables. 
a 
A separate one-way analysis of variance (ANOVA) was 
Hewlett-Packard, HP 86, Basic Statistics and Manipula-
tion Pac, Hewlett-Packard Company, 1010 N.E. Circle 
Blvd., Corvallis, OR 97330. 
~---
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performed for each of the 17 variables to determine the 
degr~e of significant difference among the three groups. 
For those variables which showed a significant difference 
for F-Test, a Scheffe's Post-hoc test (54) was performed. 
This test evaluates individual differences among the means 
of the three groups. Further, this procedure will iden-
tify the group within each variable with the greatest 
probability for having high values within the selected 
DRG category. 
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RESULTS 
§ --
As previously indicated, the 10,550 patients admitted 
to the hospital were retrospectively assigned to 390 DRGs. 
The top 20 most expensive DRGs for the pharmacy department 
in terms of total pharmacy charges are listed in Table I. 
DRGs within the major diagnostic categories (MDC). Addi-
tional financial data on the top 20 DRGs are presented 
in Table III. 
Table IV ranks the most expensive DRGs in six dif-
ferent ways, namely, total pharmacy charges per DRG, 
~--
number of patients~ pharmacy charges per patient, hos-
pital charges per patient, pharmacy charges as percentage 
of hospital charges, and LOS per patient. 
The top five most expensive medical DRGs based upon aver-
age hospital charges, average pharmacy charges, and average 
LOS are presented in Figure 2, 3, and 4, respectively. 
DRG 88 (Chronic Obstructive Pulmonary Disease) was 
chosen as the most expensive DRG category for the pharma-
cy department. This DRG category includes a total of 110 
patients, about half of them (54 patients) were Medicare 
patients. Their mean age was 69.2 years (range 50-89) 
and their total pharmacy charges were $77,931 (range 
$11.40-6492.30) with a mean of $708.70. 
The patient frequency distribution shown in Figures 
43 
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Table II 
Distribution of the 20 Most Expensive DRGs by MDC. 
Number Total 
- -- ----- -- ---
of Pharmacy 
DRGs Charges 
MDC Description of MDC 
in per MDC 
MDCa ($) 
5 Diseases and disorders of the 
4 
6 
13 
1 
7 
17 
14 
circulatory system. 
Diseases and disorders of the 
respiratory system 
Diseases and disorders of the 
digestive system 
Diseases and disorders of the 
female reproductive system 
Diseases and disorders of the 
nervous system 
Diseases and disorders of the 
hepatobiliary system and 
pancreas 
Myeloproliferative disorders 
and poorly differentiated 
malignancy and other neoplasm 
Pregnancy, childbirth, and the 
puerperium 
7 
4 
3 
2 
1 
1 
1 
1 
815,208 
308,723 
212,393 
96,978 
72,075 
57,127 
55,111 
51,543 
----------------------------------------------------------------
a 
Represents the number of DRGs to which patients with 
this MDC were assigned during the study period. 
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Table III 
a 
Pharmacy and Hospital Charges per Patient for the 
20 Most Expensive DRGs for January-August 1983. 
45 
Pharmacy 
--- -- ty-----1GS--------------Charges per 
Hospital 
('J,<:lrrrao nor 
V.lH...I..L Q'-L.I .1-''-'.L 
Pharmacy Charges 
as % of - ------
Hospital Charges DRG (days) Patient ($) 
107 
82 
148 
127 
88 
14 
96 
154 
105 
89 
197 
122 
182 
403 
132 
125 
354 
370 
110 
366 
13.2 +9.7 
10.0 ±13.4 
13.4 ±8.4 
7.4 ±10.6 
9.5 ±8.6 
9.6 ±13.9 
6.9 ±5.5 
14.8 ±12.6 
19.1 ±10.1 
7.4 ±5.7 
9.2 ±5.5 
10.7 ±26.9 
4.9 ±3.9 
11.0 ±9.9 
6.2 ±5.7 
2.7 ±2.6 
6.7 ±3.9 
5.2 ±3.5 
11.9 ±6. 9 
4.1 ±8 .2 
a 
2,698 ±1,692 
764 ±850 
1,201 ±1,579 
401 ±565 
709 ±864 
419 ±844 
545 ±660 
1,861 ±2,372 
4,267 ±2,499 
540 ±548 
601 ±795 
401 ±760 
251 +370 
984 j)' 154 
257 ±572 
118 ±248 
251 ±487 
270 ±869 
1 '009 ±1 '225 
810 ±545 
Reported as the mean ± S.D. 
b 
Patient ($) 
24,123 ±11' 160 
5.021 ±5,520 
8,690 ±6,582 
4,662 ±4,755 
6,429 ±6,948 
5,923 ±7,454 
4,813 ±5,184 
12,872 ±15,814 
35,758 ±19,250 
. 4,699 .:l-4,584 
5,950 ±5,624 
6,923 ±10,967 
2,443 ±1,992 
5,982 ±5,901 
4,004 ±5,808 
2,872 ±2,126 
3,730 ±2,183 
2.935 ±2,115 
11' 679 ±10, 759 
2,534 ±3,220 
11.2 
15.2 
13.8 
8.6 
11.0 
7.8 
11.3 
14.5 
12.0 
11.5 
10.1 
5.8 
10.3 
16.5 
6.4 
4.1 
6.8 
9.2 
8.6 
32.0 
Listed in decreasing order based upon total pharmacy 
charges per DRG, which are reported in Table I. 
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Table IV 
The 20 Most Expensive DRGs within Various Measures 
of Hospital and Pharmacy Charges. 
~- ------~ ---- - ----- - - Rank within Each Measure 
Pharmacy 
Total Pharmacy Hospital Charges 
Pharmacy Number Charge Charge as % of 
Charges of per per Hospital 
DRG per DRG Patients Patient Patient Charges 
46 
LOS 
per 
Patient 
------------------------------------------------------------------------
107 1 8 2 2 9 4 
82 2 10 8 11 3 8 
148 3 15 4 5 5 3 
127 4 5 14 14 15 12 
88 5 13 9 7 10 10 
14 6 7 13 10 16 9 
96 7 11 11 12 8 14 
154 8 19 3 3 4 2 
105 9 20 1 1 6 1 
89 10 12 12 13 7 13 
197 11 14 10 9 12 11 
122 12 9 15 6 19 7 
182 13 2 18 20 11 18 
403 14 17 6 8 2 6 
132 15 4 17 15 18 16 
125 16 1 20 18 20 20 
354 17 3 19 16 17 15 
370 18 6 16 17 13 17 
110 19 18 5 4 14 5 
366 20 16 7 19 1 19 
;d_ 
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6 and 7 illustrates the three distinct three groups used 
in this study. The three groups had an average age of 
69.3 years. A~proximately 78 percent of them were males 
(35 patients). Medicare patients represent 36 percent 
(16 patients). The total pharmacy charges were $38,268 
with a mean of $850.40. Approximately 72.7 percent of 
the 45 patients had pharmacy charges below the mean (see 
Table VI and VII). The total hospital charges for the 45 
patients were $317,502 with a mean of $7055.60. The aver-
age LOS was calculated to be 9.7 days. Demographic data 
of the three groups are summarized in Table V. 
There were three deaths among the 45 patients. It 
i s i-mp o r t ant to p o in t o u t t hat the t h r e e d e at h s , a 11 in 
group 3, were patients with the highest pharmacy charges, 
and of these three, two were labeled as pharmacy charge 
"Outliers" (mean pharmacy charges plus two standard 
deviations). 
It was found that the most prescribed drug categories 
for the 45 selected patients wer~: spasmolytics, anti-
infective agents, hormones and synthetic substances, auto-
nomic drugs, C.N.S drugs, electrolytes, cardiovascular and 
vasodilating agents. 
Seventeen variables, which were proposed to correlate 
with high pharmacy charges, were selected for analysis. 
These variables are: age, weight, number of admissions, 
number of consultations, LOS, pharmacy charges, hospital 
charges, number of drug dosage units, number of x-ray 
;:;::;; _ __:__ ; __ _ 
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Table V 
Demographic Data of the Three Groups. 
=--- -~-- -~-Data _____ ~_~ ____ §fQ_Up 
1 
Group _ _Gr-oup 
2 3 Total 
Population 
Size 15 15 15 45 
Mean age 69.2 69.6 69.0 69.3 
Sex (M:F) 11:4 11:4 13:2 35:10 
Medicare 
Patients 6 3 7 16 ; ~-
~:-_ 
~-
Smokers 12 13 12 37 ~=-
;-_;- . 
Special 
Care Days 3 13 48 64 --
--Number of 
Deaths 0 0 3 3 
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orders, number of ·microbiology tests, number of A.B.G. 
orders, number of chemistry panel 1 and 2 orders, number 
of urine analyses, number of drug serum level orders, and 
the total number of laboratory orders. Basic statistics 
of the 17 variables of the randomly selected 45 patients 
are summarized in Tables VI and VII. 
The correlation matrix of the 17 variables was calcu-
lated. The most significant findings are the following: 
1. Age, weight, and number of admissions of the 45 
patients did not seem to correlate well with the rest of 
the 17 variables (correlation coefficient, r< 0.3). 
2. LOS was highly correlated with pharmacy charges 
(0.859), hospital charges (0.915), ·number of drug dosage 
units (0.907), number of drug level orders (0.838), number 
of total laboratory orders (0.858), number of x-ray orders 
(0.834), number of microbiology orders (0.618), number of 
blood analyses (0.784), number of A.B.G. orders (0.700), 
and number of chemistry panel 1 and 2 orders (0.754). 
3. Pharmacy charges were highly correlated with hos-
pital charges (0.949), number of drug level orders (0.784), 
number of total laboratory orders (0.910), number of A.B.G. 
orders (0.813), number of drug dosage units (0.944), number 
of blood analyses (0.844), number of x-ray orders (0.885), 
number of microbiology orders (0.677), and number of chem-
istry panel 1 and 2 orders (0.766). 
4. Hospital charges correlated well with the number 
of drug dosage units (0.922), the total number of labora-
§ 
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Table VI 
Order Statistics of the Selected Seventeen Variables. 
__ 'lariabLe _______ -~ __ 
-- --- --- - -- ---
Names Maximum Minimum tvlidrange fvledian 
Age 92 so 71 69 
Weight (Kg) 140 36 88 70 
# of Admissions 21 1 11 5 
# of Consultations 2 0 1 0 
L 0 S 41 1 21 8 
Pharmacy Charges 6492.3 27.3 3259.8 495.2 
Hospital Charges 53636.9 928.1 27282.5 4887 
# of Drug Dosage Unit 454 4 229 62 
# of X-Ray 26 0 13 1 
# of Microbiology 12 0 6 2 
# of A. B. G 49 0 24.5 2 
# of Chemistry Panel 
1 and 2 23 0 11.5 2 
# of Urine Analysis 2 0 1 0 
# of E. K. G 3 0 1.5 1 
# of Blood Analysis 30 0 15 1 
# of Drug Levels 24 0 12 2 
# of Total Labs. 165 3 84 13 
25-th 
% 
62 
56 
2 
0 
6 
327 
3333 
33 
1 
1 
1 
1 
0 
0 
1 
1 
8 
so 
73 
80 
7 
1 
11 
968.3 
7617 
108 
2 
3 
4 
6 
1 
1 
2 
3 
23 
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Table VII 
Basic Statistics of the Selected Seventeen Variables. 
-----------Variable--------------- Hean- Standard Standard ----------
Names (N=45) Deviation Error 
--------------------------------------------------------------
Age 69.3 10.2 1.5 
Weight (Kg) 70.2 18.6 2.8 
# of Admissions 5.7 4.8 0.7 
# of Consultations 0.4 0.6 0.1 
L 0 s 9.7 6.6 0.9 
Pharmacy Charges 850.4 1067.4 159.1 
Hospital Charges 7055.6 7930.5 1182.2 
# of Drug Dosage Unit 84.6 80.5 12.0 ~ -# of X-Ray 2.2 3.9 0.6  
# of Microbiology 2.4 2.9 0.4 
~---
~ 
~--
# of A. B. G . 4. 5 7.9 1.2 
~---
# of Chern. Panel 1 & 2 4.2 4.7 0.7 
~--
# of Urine Analysis 0.5 0.6 0.1 -
-
# of E. K. G 0.8 0.7 0.1 
# of Blood Analysis 2.3 4.4 0.7 ~ --
# of Drug Levels 2.9 4.1 0.6 
# of Total Laboratories 19.9 24.8 3.7 
--- - ------- --- -----~~----
~---- ~------
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tory orders (0.964), number of x-ray orders (0.948), number 
of A.B.G. orders (0.894), number of blood analysis orders 
(0.919), the number of drug level orders (0.870), number 
of microbiology orders (0.628), and number of chemistry 
panel 1 and 2 orders (0.743). 
5. The number of drug level orders correlates well 
with the number of total laboratory orders (0.899), number 
of x-ray orders (0.824), number of A.B.G. orders (0.809), 
number of blood analysis orders (0.814), number of micro-
biology orders (0.560), and number of chemistry panel 1 
and 2 orders (0.690). 
6. The number of blood analyses correlated with the 
number of x-ray orders (0.933), number of A.B.G. orders 
(0.846), number of chemistry panel 1 and 2 orders (0.671), 
and the number of microbiology orders (0.564). 
One-way analysis of variance results, shown in Table 
VIII, revealed that there was no significant difference 
between the three groups regarding age, weight, number of 
admissions, number of urine analyses, number of E.K.G. 
orders, or the number of blood analysis orders. In con-
trast, it was found that differences in LOS, pharmacy 
charges, hospital charges, number of drug dosage units, 
number of chemistry panel 1 and 2 orders, and the number 
of drug level orders were highly significant (P< 0.001). 
In addition, differences among the three groups regarding 
number of consultations, number of microbiology tests, 
number of A.B.G. orders, and the total number of labora-
~--
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Table VIII 
One-Way Analysis of Variance. 
Variable Mean F p 
Names Group Group Group Ratio Value 
1 2 3 
-----------------------------------------------------------------
Age 69.2 69.6 69.0 0.01 NS 
Weight (Kg) 65.5 67.3 77.7 1.97 NS 
# of Admissions 6.7 5.1 5.3 0.54 NS 
# of Consultations 0.3 0.3 0.7 3.57 0.050 
L 0 S 6.1 8.3 14.9 10.10 0.001 
Pharmacy Charges 238.5 508.2 1768.3 13.78 0.001 
Hospital Charges 3281.7 5274.0 12611.0 7.44 0.001 
# of Drug Dosage Unit 30.8 60.8 162.3 20.90 0.001 
# of X-Ray 1.2 1.3 4.1 2.73 NS 
# of Microbiology 1.6 1.5 4.0 3.95 0.050 
# of A. B. G 1.8 2.6 9.1 4.34 0.050 
# of Chemistry Panel 
1 and 2 2.1 2.3 7.7 9.75 0.001 
# of E. K. G 0.7 0.7 0.9 0.17 NS 
# of Urine Analysis 0.4 0.5 0.5 0.22 NS 
# of Blood Analysis 1.4 1.6 3.8 1.41 NS 
# of Drug Levels 1.2 1.9 5.8 7.23 0.001 
# of Total Labs. 10.5 12.9 36.2 6.05 0.005 
NS= No significant difference. 
F,-=-----=-
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tory orders were found to be significant (P< 0.05). 
Results of Scheffe's test for the ten statistically 
significant variables are presented in Table IX. The 
results revealed that the mean number crf consultations 
and microbiology tests among group 1, 2, and 3 was not 
statistically significant. However, the difference be-
tween group 3 mean and the averaged mean of group 1 and 2 
was statistically significant (P< 0.05). On the other 
hand, the difference between group 3 and either group 1 
or group 2 regarding LOS, pharmacy charges, hospital 
charges, the number of drug dosage units, number of chem-
istry panel 1 and 2, and number of drug level orders was 
found to be statistically significant (P< 0.05). 
In addition, it was found that the difference between 
group 1 and group 2 with regard to these ten variables was 
not statistically significant. 
The number of A.B.G. ordered showed a statistically 
significant difference between group 1 and 3. However, 
no statistical difference was found to exist between 
group 1 and 2 or even between group 2 and 3. 
One of the important findings was that LOS, pharmacy 
charges, hospital charges, the total number of laboratory 
orders, number of drug dosage units, and number of drug 
level orders are highly correlated. In addition, Table 
VIII shows that the mean difference among the three groups 
regarding these six variables was highly significant (P< 
0.005). 
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Table IX 
a 
Summary Results of Scheffe's S Test. 
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Variable 
Names 
# of Consultations 
L 0 S 
Pharmacy Charges 
Hospital Charges 
# of Drug Dosage Unit 
# of Microbiology 
# of A. B. G 
# of Chemistry Panel 
1 and 2 
# of Drug Levels 
# of Total Laboratories 
a 
Group 
1 & 3 
NS 
P<0.01 
P<0.01 
P<0.01 
P<0.01 
NS 
P<0.05 
P<0.01 
P<0.01 
P<0.05 
Group 
2 & 3 
NS 
P<0.01 
P<0.01 
P<0.05 
P<0.01 
NS 
NS 
P<0.01 
P<0.05 
P<0.05 
Group 
1 & 2 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
NS 
· NS 
Group 3 Vs. 
Group 1 & 2 
P<0.05 
P<0.05 
Variables having a statistically significant F-Test value. 
NS= No significant difference. 
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DISCUSSION 
It was theorized that identifying the 20 most ex-
pensive DRGs, based upon pharmacy charges, would serve 
as the initial step for the pharmacy department to res-
pond to the prospective payment system. The analysis of 
--·-· ·- ---t-he--t-u-p-------z-e-D-R-6-s-r-e-v-e-a-1-e-d --t-ha-t DRG- -1-0~-- (Go r-o-na r-y--- By pa-s s--J 
had the highest total pharmacy charges and was second, 
next to DRG 105 (Cardiac Valve Procedure With Pump), 
with respect to average hospital charges. 
Major diagnostic category 5 (Diseases and Disorders 
of the Circulatory System) was the highest for the total 
hospital charges. This was expected since the hospital 
provides the only open-heart surgery services in the com-
munity (48). 
Table IV demonstrates that the ranking based upon mean 
hospital charges per patient and the mean LOS are quite 
similar. However, further statistical evaluation of LOS 
and hospital charges is required for these parameters to 
be used as reliable predictors of DRGs with expensive 
pharmacy charges. Therefore, Directors of Pharmacy should 
be cautioned when attempting to identify DRGs for special 
attention. 
It is important to point out that the actual ranks 
reported in Tables I-IV may not be applicable to other 
hospitals due to variation of charge systems from one 
56 
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hospital to another. However, the method could be ap-
plied to other institutions. The problem of assuring 
that the charges reported in this study accurately re-
fleet the cost of providing pharmaceutial services is an 
important limitation of the study approach. An ideal 
approach for establishing pharmacy priorities would be to 
determine the actual direct and indirect costs per case 
and compare those cbsts with the actual reimbursement. 
However, data on actual costs are generally not available 
in most hospitals (48). 
Only medical DRGs were included in the analysis of 
this study. Surgical and neoplastic categories were ex-
eluded from the study since these two categories utilize 
either non-drug procedures, high cost equipment, and / or 
investigational chemotherapeutic agents. 
DRG 88 (Chronic Obstructive Pulmonary Diseases- COPD) 
was found to fit the criteria established to select the 
most expensive DRG category (see page 32). This medical 
category had the highest average pharmacy charge~, high 
mean hospital charges, LOS, and patient census (see Table 
I and Figures 2, 3, and 4). 
Being a chronic disease, the number of admissions 
per patient in DRG 88 varied greatly from one to 21 ad-
missions (Table VI). In contrast, the number of consul-
tations varied from zero to two consultations per pa-
tient. There were two cases that exhibited the maximum 
number of consultations. These two cases also had the 
R---
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highest pharmacy charges of the patients reviewed, 
Therefore, patients requiring medical consultations 
should be carefully monitored. 
It was calculated that about 72 percent of the se-
lected 45 patients had pharmacy charges below the mean. 
That is an encouraging result since the pharmacist's ef-
forts could therefore be focused on about one-fourth of 
the patients assigned to this particular DRG rather than 
the entire population. 
It was found that the average LOS, average pharmacy 
charges, and average hospital charges of the randomly 
selected 45 patients, although slightly higher, were 
similar to those calculated for the entire population of 
DRG 88 (9.7 days, $850, $7055 versus 9.5 days, $709, and ~--
$6429 respectively). This indicates that the randomly 
selected 45 patients may closely represent DRG 88 pa-
tients. That finding is also important since the statis-
tical analysis will be expected to reflect the same out-
comes when appplied to the rest of the patients within 
the selected DRG, i.e., it is a representative sample. 
Correlation matrix results of the 17 variables re- ill 
vealed that there was no correlation between age, weight, 
or the number of admissions and the rest of the 17 var-
iables, For example, being an old patient does not mean 
having high pharmacy or hospital charges. Similarly, 
neither the frequency of admission nor being obese had an 
effect on pharmacy charges. Further, the differences 
59 
among the three identified groups for those same three 
variables were not statistically significant. Therefore, 
these three variables may be excluded as being important 
predictors of high pharmacy charges. 
It was found that LOS, pharmacy charges, hospital 
charges, and number of drug dosage units within the se-
lected DRG were highly correlated. Further, the dif-
ference among the three groups regarding the above men-
tioned four variables was highly significant. Therefore, 
there was a direct relationship between LOS, hospital 
charges, and pharmacy charges within DRG 88. 
More impressively, hospital charges were found to be 
correlated very well with the number of drug dosage units, 
number of drug level orders, and the total number of lab-
oratory tests performed, in addition to its correlation 
with LOS and pharmacy charges. This is an important in-
dicator that could be utilized by pharmacy staff to inten-
sively monitor abnormal patients. For example, by com-
paring the means of the mean values of the 17 variables 
of group 2 and group 3 presented in Table VIII, the fol-
lowing patients may be c~ndidates for intensive monitoring 
by clinical pharmacists: 
a. Patients requiring more than ten drug dosage 
units per day (range 5.2-13.9). This was calculated as 
a 
follows: 
a 
These mathematical calculations were similarly 
performed for all the 17 variables of group 2 & 3 
presented in Table VIII. 
g_ 
~----
Number of drug dosage (Mean DDUs of group 2 + 3) /2 
units (DDUs) per day = ------------------------------
(Mean LOS of group 2 + 3) /2 
(60.8 + 162.3) /2 111.55 
60 
DDUs per day = ----------------- = ------ = 9.6 
(8.3 + 14.9) /2 11.6 
Range of the DDUs = the DDUs of group 2/ mean LOS to 
the DDUs of group 3/ mean LOS 
60.8 162.3 
= to = 5.24 to 13.99 
11.6 11.6 
b. Patients requiring more than four drug serum 
level analyses (range 1.9-5.8) during their stay. 
c. Patients receiving more than 25 laboratory tests 
(range 12~9-36.2) throughout their stay. 
d. Patients having a LOS of more than 12 days 
(range 8.3-14.9). 
e. Patients having pharmacy charges of more than 
$98 per day (range $43.81-$152.44). 
Priorities to re-evaluate and redirect pharmaceutical as 
well as other hospital resources to those patients will 
be a reasonable goal. 
It is expected that patients with a high number of 
consultations and total number of laboratory orders may 
indicate a severely ill patient and therefore, may be 
expected to consume a high number of drug dosage units. 
Since drug dosage units correlate with pharmacy charges 
and hospital charges, those patients may be expected to 
have high hospital charges. 
~-
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It is important to point out that although patients 
selected for this study were not all Medicare patients 
(see Table V), it is predicted that analysis of DRG 88 
restricted to Medicare patients may reveal higher pharma-
cy and hospital charges. However, the significance and 
validity of such an assumption requires further inves-
tigation. 
In reviewing the patients' medical records, it was 
found that the most frequently prescribed drugs for pa-
a 
tients within DRG 88 were in the following categories: 
1. Spasmolytics (e.g., Theophylline). 
2. Anti-infective drugs (e.g., Ampicillin). 
3. Hormones and synthetic substances (e.g., Hydro-
cortisone). 
4. Autonomic drugs: Sympathomimetic agents (e.g., 
Metaproterenol and Albuterol). 
5. C.N.S. drugs: Sedative and hypnotics (e.g., 
Diazepam). 
6. Electrolytic, caloric, and water balance: 
Diuretics (e.g., Furosemide). 
7. Cardiovascular drugs: Cardiac (e.g. Digoxin). 
8. Cardiovascular drugs: Vasodilating agents 
(e.g., Nitroglycerin). 
As a result, clinical pharmacists should review drug doses 
and route and frequency of administration of these drug 
a 
Based upon the American Hospital Formulary Service 
Classification, 1982. 
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categories. In addition, therapeutically equivalent 
alternative drugs with lower costs should be purchased 
and administered. ~ c ~--
Eighty two percent of the selected 45 patients were 
found to be chronic or heavy smokers (37 patients). The 
rest of the 45 patients (8 patients) were either non-
smokers or their smoking status was not reported in their 
medical records. Therefore, although it is apparent that 
smokers are approximately equally distributed among the 
three patient groups, smoking status may be further in-
vestigated and statistically tested as being a predis-
posing factor for recurrent pulmonary problems, high 
pharmacy and hospital charges, and frequent hospital 
~-
admission. 
~ ---'----
There were three deaths among the randomly selected 
45 patients, all in group 3. The first case was a 50 year 
old female who had a LOS of 10 days, and a total number 
of labor~tory orders of 46. She had a non-Hodgkins lym-
phoma of the lung and died from pulmonary fibrosis and 
respiratory failure. The second case was a 61 year old II 
male who had a LOS of 20 days and 45 laboratory tests. 
That patient had a long history of myocardial arrhythmia 
and diabetes mellitus. Surgical exploration was per-
formed because of unknown diagnosis and sepsis of unknown 
etiology. The surgical exploration led to increased LOS 
with the resultant high hospital charges. The third case 
was a 84 year old male who had been hospitalized for 41 
63 
days and had a total of 165 laboratory tests. He had 
bulla of his upper lobe, in addition to a Pseudomonas 
infection and lung cancer. This severely ill patient died 
from the combination of respiratory and renal failure. 
These three deaths represent the three most expensive pa-
tients regarding both pharmacy and hospital charges. 
Therefore, patients admitted with serious secondary di-
agnoses or those who are apparently severely ill should 
be intensively monitored. 
Finally, it is important to emphasize that none of 
the proposed parameters may be expected to influence 
pharmacy or hospital charges by itself but rather they 
should be considered as interdependent parameters. In 
addition, it should be acknowledg~d that these parameters 
could not be applied immediately upon a patient's ad-
mission. However, these parameters may be expected to 
be used for patients who are likely to exceed the pro-
posed values. 
~­
~----
SUMMARY AND CONCLUSION 
The Prospective Payment System is revolutionary in 
that hospitals will be reimbursed based upon DRG rates or 
other payment system regardless of the actual hospital 
cost, the amount of service rendered, or LOS. Therefore, 
---there -is_a_crear--fnceriti-ve for liosp-itals to minimize-costs ___ _ 
in order to survive. A correlation between clinical and 
financial data was suggested to describe the case cost or 
the end product cost. Yet, no study was published to 
achieve this goal. Because of the current payment sys-
tern, pharmacy departments are establishing cost reduction 
as a top priority. Evaluating DRGs with high pharmacy 
charges was suggested as the first step. 
The present study establishes the second step in the 
process: to identify predictors of expensive DRGs for the 
pharmacy department. Expensive DRGs based upon their 
total pharmacy charges were evaluated in an attempt to 
identify and propose predictors that may influence pharma-
cy charges. It is suggested that clinical pharmacists, 
guided by these predictors, will intensify their monitor-
ing of patients within DRG 88 to reduce pharmacy costs. 
Diagnosis Related Group 88, COPD, was identified as 
the most expensive medical DRG for the pharmacy depart-
ment. This DRG consisted of 110 patients admitted dur-
ing a nine month period in 1983. For the purpose of the 
64 
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present study, 45 out of 110 patients were randomly se-
lected from three distinct subgroups. Seventeen-variables 
were chosen to determine if they may directly correlate 
with pharmacy charges. 
Results of the correlation matrix for the selected 
17 variables showed no significant correlation between 
age, weight, and number of admissions and the rest of the 
17 variables. Therefore, it is suggested that these three 
variables are not appropriate predictors of patients in 
DRG 88 with high pharmacy charges. 
The number of drug dosage units, number of drug level 
orders, and pharmacy charges were significantly correlated 
with hospital charges and patient's LOS. Therefore, the 
total number of drug dosage units consumed, number of drug 
level analyses, and pharmacy charges may serve as pre-
dieters of high hospital charges and long LOS. 
On the other hand, the difference among the three 
groups regarding number of admissions, number of x-ray 
orders, number of E.K.G., the number of blood analysis 
orders, number of urine analysis orders, age, or weight 
were found to be statistically insignificant. Therefore, 
these variables may not be predict~rs of high pharmacy 
or hospital charges within DRG 88. 
Scheffe's test showed no significant difference be-
tween the mean of group 1 and 2 for the ten statistically 
significant variables (see Table VIII). However, there is 
a highly significant difference between the mean of group 
~-
~-­
i-i-
~-
~ 
~ 
I 
-------------- -----
-- ---- --- -- ---- --------
66 
3 and 1 as well as those of group 3 and 2 (P< 0.01) with 
the exception of the number of microbiology orders, number 
of consultations, and number of A.B.G. orders (see Table 
IX). Therefore, group 2 and 3 represent the "break" point 
to which pharmaceutical service efforts should be direct-
ed to effectively reduce pharmacy charges. 
In summary, this study attempted to provide a use,ful 
guide for clinical pharmacists on how to deal with pro-
spective payment system by identifying those DRGs creating 
financial problems for the pharmacy department. In ad-
dition, this study proposed a methodological plan that 
can be used in other institutions. Clinical pharmacists 
could then adjust their resources and personnel to encom-
pass exceptional cases. 
Finally, the following patient characteristics and 
criteria, based upon the mean values of group 2 and 3 
presented in Table VIII, are proposed as predictors of 
patients who may have high pharmacy and hospital charges: 
1. Patient age, weight, number of admissions, 
number of x-ray orders, number of E.K.G. tests, number 
of urine analyses, or number of blood analysis orders 
are expected to have no influence on pharmacy charges 
or hospital charges. 
2. Patients who have a LOS of more than 12 days. 
3. Patients requiring one or more consultations. 
4. Patients receiving more than ten drug dosage 
units per day. 
~ 
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5 . Patients requiring mi~robiology or culture and 
sensitivity tests exceeding three tests throughout his 
hospital stay. E=i----
: 
6 . Patients requiring more than six A.B.G. tests. 
7. Patients requiring more than five combined 
chemistry panel 1 and 2 analyses. 
------------~ _ _____!'_a_!_~en~13__l:"e<:_~i'.'_~n~ more than a t_c:>t_a~ ()f 25 1_a_b: ______ _ 
oratory tests. 
9. Patients receiving more than four drug level 
analyses. 
10. Patients having pharmacy charges of more than 
$98 per day and I or hospital charges of more than $771 
per day. g_ 
M--
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APPENDIX A 
a 
Definition of Case-Mix Data Items. 
76 
1. Admission class: 
The circumstances under which the patient entered 
the hospital and should include separate catego-
ries for at least emergency/urgent and elective. 
2. Admission diagnosis: 
--~------ -- --------T-h_e_d_i_a_g_n_O_S __ i_S ___ pr-ov-i-de_d_ Otl ad-m-ission- as- ex-plain-ing-------
the reason for admission (coded using ICD-9-CM). 
3. Atte~ding service: 
The major department in which a patient is treated 
and is determined by the specialty of the physi-
cian attending to the principal diagnosis. 
4. Major diagnosis: 
That diagnosis ac~ounting for the greatest resource 
consumption durin~ a patient stay (i.e., accounting 
for the greatest number of days or costs for the 
stay) • 
. . 5. Major Procedure: 
That procedure most related·to major diagnosis. 
6. Principal diagnosis: 
That condition established after study as being 
chiefly responsible for occasioning the admission 
of patient to the hospital for care (coded using 
ICD-9-CM). 
7. Principal procedure: 
a-The only procedure performed, 
b-The only therapeutic procedure performed or 
c-The therapeutic procedure performed that is most 
related to the principal diagnosis. The number 
and types of procedures performed which deter-
mined which of these rules apply (coded using 
ICM-9-CM). 
8. Secondary diagnosis: 
a 
Conditions that exist at the time of admission or 
developed subsequently which reflect the treatment 
received and/or LOS. The record should allow for 
at least five secondary diagnoses. 
Adopted from Reference 6, Appendix A, pp. 79-81. 
b_ 
,---------------------------------------------------- --
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APPENDIX B 
Definition of Outliers. a 
Outliers 
Those patients with unusually long (day outliers) or 
costly (cost outliers) stay for a particular DRG. This 
cremental) cost of treating atypical patients. 
A. Day outliers 
Patients whose length of stay (excluding days not 
covered by plan A) exceed the average (mean stay for a 
DRG by 20 days or 1.9 Standard Deviation units), which-
ever results in a smaller number of days. 
Additional payment for day outliers are made auto-
matically on a per diem basis, i.e., the hospital does 
not have to request additional payment. 
B. Cost outliers 
Patients whose charges adjusted to cost exceed the 
DRG payment rate by the larger of $12,000 or multiple of 
1.5 times the relevent DRG payment rate, whichever yields 
the greater amount. 
Unlike day outliers, cost outliers are handled on an 
exceptional basis, i.e., a hospital must submit a written 
request to its intermediary for additional payment. 
a 
Based upon definition mentioned in Reference 52, 
pp. 7-11. 
= 
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APPENDIX C 
Chemistry Panel 1 and 2 Order Forms 
Chemistry Panel 1 
0 Electrolyte Profile 
. 0 • ~-m:;!dr I 0 I A;;;s~i-85) u IU/~ Glucose: fasting (70·1 ~I 
b1 , .. 0 --Sodiu..-n-(-1-36-1-43;-- ·--m-moi7L Glucose: _:__hr~ p.c~ . mg/dl lJ Lipase (~241 IU/d 
0 1~otassium (3~5 -4.6) m moi/L D 'B.u.N. 1!5-241 mg/dl D Acid Phosphatase 10.0.81 IU/L 
D Chloride (g'iM 061 m moi/L 0 1'Creatinine (0.6-1.2) mg/dl D 'Ark. Phosphatase (25-97) IU/L 
0 Carbon Dioxide (;~.~f) mmoi/L D ,..Uric Acid IM2~~~'7~11 mg/dl D 'SGOT (ASTI (25-411 IU/L 
0 Anion Gap. ra·Cc~~{4 \Co2)} 0 1"-r: t p t with Alb. & I Gl bul' 0 • ro ·calc, Globulin ° '" g/dl 0 SGPT (AL Tl (3·36) IU/L 
0 Calcium ,s (8.5-10.11 mg/dl 0 ~otal protein ls".o-7.81 g/dl 0 ~GT ("f GT)(~ \ ~~) IU/L 
0 Phosphorus (2."!5.4.91 mg/dl 0 Albumin (3.6-5.4) g/dl 0 Ammonia ( 11 ~351 J,lmoi/L 
0 Magnesium (1.8-2.4) mg/dL 0 Bilirubin total lies; than 1.51 mg/dl 0 Acetone 
0 OsmolalitY f2•:;.3oa> mOsm/l<g 0 Bilirubin direct (less than 0.4) mg/dl l'EJ ... 299.4 
0 Lactic Acid (0.5-2.2) mEq/L 0 Bilirubin indirect mg/dl 
Chemistry Panel 2 
Chemistry Profile l"lasma Na'...~ 
+ Serum Chem. 0 T1* Uptake 101 T.• 0 Serum Iron (42-1361 mcg/dl 
.- Total CPK and LDH 0 TJBC (250-3601 mcg/dl c Cardiac Profile F.ree Thyroxin Index, T1 & T. • 
-
Isoenzyme if increase 0 ~---------------------------· r- CPK (0-961 IU/L 0 T1 By RIA* Saturation (14471 % ~ 
r-- LOH (43-991 IU/L 0 TSH• 0 Haptoglobin normal mg/dl ._ (27-1391 
I.- CPJ( Isoenzyme 101 LOH Isoenzyme 1r IU Neonatal PKU, T4, Galactosemia• 0 Glucose Tolerance 8 Hrs. ~ 
Cardiac Rehab Profile 0 Contsot• Drawn @ 0 Creatinine Clearance e \sERUM CREAl" 
------------------- 0 f!erum 13·HCG · I Potauium 13.&-4.81 mmf/L Qual, Pregnancy Test I Pt. Hgl ~l l LEVEL REO. 
-------------------
r....-. Serum B·HCG• !0 GluCOM 170-1101 -mg/dl Amylase (Urinal . Cone. ____ U/L 11..-1 Quantitive 
D Choleetarol (12D=2all mg/dl 0 Upid Profile• (Normal Range 5-37 U/2 Hr.) U/2 Hr. 
1.- Triglyceride 130-2001 mg/dl 0 ABC-Folate• Total Vol. mi. L Hr. ""'- Urine 
....., 
HDL Chola.terol { M 32·72) mg/dl 0 VItamin B-12* D Other ~ FJ9..96 ----------------------~----lr-"l Total Chol: HDL Chol. Ratio 0 Ferritin• 
